On Monday, Bristol Myers Squibb completed its acquisition of Boston drug developer Karuna Therapeutics Inc. for $14 billion. Karuna is a spinout of Boston-based PureTech Health, which will receive hundreds of millions of dollars from its stake in Karuna. Here’s what it plans to do withe the proceeds.
Source link
PureTech made millions on Karuna acquisition. Here’s what it plans to return to shareholders.
![](https://fuerza943.com/wp-content/uploads/2024/03/daphne-zohar-puretech-founder-and-ceo100xx2730-2730-683-0.jpg)